Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular and Genetic Abnormalities in Myeloid Neoplasms (LMA Brasil)
NCT02084563Phase 2Completed
- Sponsor
- Hospital Israelita Albert Einstein
- Start
- Oct 2012
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cytarabine, daunorubicin, decitabine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), Myeloproliferative Neoplasm (MPN), sponsored by Hospital Israelita Albert Einstein. Started Oct 2012; status: completed.
02
Drugs
cytarabinedaunorubicindecitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT02084563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02084563.